OverviewSuggest Edit
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Sunesis is committed to advancing its lead drug candidate, QINPREZO (vosaroxin), through clinical trials. QINPREZO is an anti-cancer quinolone derivative, or AQD — a class of compounds that has not been used previously for the treatment of cancer.
| Type | Public | |
| Founded | 1987 | |
| HQ | South San Francisco, US | Map |
| Website | sunesis.com | |
| Employee Ratings | More |
Recent NewsAll News
- Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting
- Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
- Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights
- Sunesis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
Key People/Management at Sunesis Pharmaceuticals
Daniel Swisher
Sunesis Pharmaceuticals Office Locations
Sunesis Pharmaceuticals Financials and Metrics
Sunesis Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (Q3, 2018) | (6.5m) |
EBIT (Q3, 2018) | (6.3m) |
Market capitalization (13-Feb-2019) | 19.8m |
Closing stock price (13-Feb-2019) | 0.5 |
Cash (30-Sep-2018) | 20.2m |
EV | 14.4m |
| USD | Q1, 2014 | Q3, 2014 | Q2, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.0m | 854.0k | 854.0k | 640.0k | 610.0k | 610.0k | 669.0k | 237.0k | 237.0k | ||
General and administrative expense | 3.4m | 7.2m | 5.2m | 4.3m | 4.0m | 3.9m | 3.9m | 3.7m | 3.4m | 2.8m | 2.7m |
R&D expense | 7.6m | 6.9m | 6.3m | 6.2m | 6.6m | 5.3m | 6.2m | 4.9m | 4.0m | 3.8m | 3.6m |
Operating expense total | 11.0m | 14.2m | 11.5m | 10.5m | 10.6m | 9.1m | 10.1m | 8.6m | 7.3m | 6.6m | 6.3m |
| USD | Q1, 2014 | Q3, 2014 | Q2, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 50.4m | 20.8m | 20.3m | 23.9m | 9.4m | 5.8m | 11.5m | 11.7m | 21.4m | 17.0m | 20.2m |
Current Assets | 71.8m | 46.0m | 40.7m | 40.7m | 34.0m | 25.1m | 35.9m | 23.5m | 26.9m | 21.9m | 21.5m |
PP&E | 41.0k | 53.0k | 19.0k | 11.0k | 8.0k | 6.0k | 1.0k | 25.0k | 18.0k | 16.0k | 14.0k |
Total Assets | 71.8m | 46.1m | 40.7m | 40.7m | 34.0m | 25.1m | 35.9m | 24.9m | 27.0m | 22.0m | 21.6m |
| USD | Q1, 2014 | Q3, 2014 | Q2, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (14.6m) | (41.7m) | (18.1m) | (10.1m) | (20.5m) | (29.5m) | (9.8m) | (18.7m) | (7.3m) | (14.1m) | (20.6m) |
Depreciation and Amortization | 5.0k | 18.0k | 22.0k | 3.0k | 6.0k | 8.0k | 2.0k | 4.0k | 2.0k | 4.0k | 6.0k |
Accounts Payable | 58.0k | (181.0k) | (895.0k) | 128.0k | 306.0k | 73.0k | 776.0k | 406.0k | (659.0k) | (144.0k) | (420.0k) |
Cash From Operating Activities | (11.4m) | (34.2m) | (19.8m) | (10.7m) | (20.1m) | (29.0m) | (9.7m) | (20.5m) | (6.5m) | (12.4m) | (17.9m) |
| USD | Y, 2018 |
|---|---|
EV/EBIT | -2.3 x |
EV/CFO | -0.8 x |
Debt/Equity | 1.6 x |
Debt/Assets | 0.7 x |
Financial Leverage | 2.3 x |
Sunesis Pharmaceuticals News and Updates
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting
Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights
Sunesis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
Sunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference
Sunesis Pharmaceuticals Company Life and Culture
Sunesis Pharmaceuticals Frequently Asked Questions
When was Sunesis Pharmaceuticals founded?
Sunesis Pharmaceuticals was founded in 1987.
Who are Sunesis Pharmaceuticals key executives?
Sunesis Pharmaceuticals's key executives are Daniel Swisher.
How many employees does Sunesis Pharmaceuticals have?
Sunesis Pharmaceuticals has 34 employees.
What is Sunesis Pharmaceuticals revenue?
Latest Sunesis Pharmaceuticals annual revenue is $669 k.
What is Sunesis Pharmaceuticals revenue per employee?
Latest Sunesis Pharmaceuticals revenue per employee is $19.7 k.
Who are Sunesis Pharmaceuticals competitors?
Competitors of Sunesis Pharmaceuticals include Karo Pharma, Sareum Holdings and MolMed.
Where is Sunesis Pharmaceuticals headquarters?
Sunesis Pharmaceuticals headquarters is located at 395 Oyster Point Boulevard, South San Francisco.
Where are Sunesis Pharmaceuticals offices?
Sunesis Pharmaceuticals has an office in South San Francisco.
How many offices does Sunesis Pharmaceuticals have?
Sunesis Pharmaceuticals has 1 office.